Search

Your search keyword '"Myers, Kasiani"' showing total 535 results
Start Over Author "Myers, Kasiani" Publication Type Academic Journals
535 results on '"Myers, Kasiani"'

1. Liver disease and transplantation in telomere biology disorders: An international multicenter cohort.

Author

Wang, YunZu, Kaj-Carbaidwala, Batul, Lane, Adam, Agarwal, Suneet, Beier, Fabian, Bertuch, Alison, Borovsky, Kristin, Brennan, Steven, Calado, Rodrigo, Catto, Luiz, Dufour, Carlo, Ebens, Christen, Fioredda, Francesca, Giri, Neelam, Gloude, Nicholas, Goldman, Frederick, Hertel, Paula, Himes, Ryan, Keel, Sioban, Koura, Divya, Kratz, Christian, Kulkarni, Sakil, Liou, Iris, Nakano, Taizo, Nastasio, Silvia, Niewisch, Marena, Penrice, Daniel, Sasa, Ghadir, Savage, Sharon, Simonetto, Douglas, Ziegler, David, Miethke, Alexander, and Myers, Kasiani

Subjects
Humans, Liver Transplantation, Female, Male, Retrospective Studies, Adult, Middle Aged, Telomere, Adolescent, Liver Diseases, Young Adult, Child, Treatment Outcome, Child, Preschool
Abstract

BACKGROUND: Patients with telomere biology disorders (TBD) develop hepatic disease, including hepatitis, cirrhosis, and hepatopulmonary syndrome. No specific treatment exists for TBD-related liver disease, and the role of liver transplantation (LT) remains controversial. Our study objectives were to describe the clinical characteristics, management, and outcomes in patients with TBD-related liver disease, and their LT outcomes. METHODS: Data from 83 patients with TBD-associated liver disease were obtained from 17 participating centers in the Clinical Care Consortium of Telomere-Associated Ailments and by self-report for our retrospective, multicenter, international cohort study. RESULTS: Group A (Advanced) included 40 patients with advanced liver disease. Of these, 20 underwent LT (Group AT). Group M (Mild) included 43 patients not warranting LT evaluation, none of whom were felt to be medically unfit for liver transplantation. Supplemental oxygen requirement, pulmonary arteriovenous malformation, hepatopulmonary syndrome, and higher bilirubin and international normalized ratio values were associated with Group A. Other demographics, clinical manifestations, and laboratory findings were similar between groups. Six group A patients were declined for LT; 3 died on the waitlist. Median follow-up post-LT was 2.9 years (range 0.6-13.2 y). One-year survival post-LT was 73%. Median survival post-LT has not been reached. Group AT patients had improved survival by age compared to all nontransplant patients (log-rank test p = 0.02). Of 14 patients with pretransplant hypoxemia, 8 (57%) had improved oxygenation after transplant. CONCLUSIONS: LT recipients with TBD do not exhibit excessive posttransplant mortality, and LT improved respiratory status in 57%. A TBD diagnosis should not exclude LT consideration.

Published
2024

3. Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients.

Author

Zinter, Matt, Brazauskas, Ruta, Strom, Joelle, Chen, Stella, Bo-Subait, Stephanie, Sharma, Akshay, Beitinjaneh, Amer, Dimitrova, Dimana, Guilcher, Greg, Preussler, Jaime, Myers, Kasiani, Bhatt, Neel, Ringden, Olle, Hematti, Peiman, Hayashi, Robert, Patel, Sagar, Rotz, Seth, Badawy, Sherif, Nishihori, Taiga, Buchbinder, David, Hamilton, Betty, Savani, Bipin, Schoemans, Hélène, Sorror, Mohamed, Duncan, Christine, Phelan, Rachel, Dvorak, Christopher, De Oliveira, Satiro, and Winestone, Lena

Subjects
Humans, Child, United States, Hematopoietic Stem Cell Transplantation, Transplant Recipients, Transplantation, Homologous, Graft vs Host Disease, Critical Care
Abstract

Allogeneic hematopoietic cell transplantation (HCT) can be complicated by life-threatening organ toxicity and infection necessitating intensive care. Epidemiologic data have been limited by single-center studies, poor database granularity, and a lack of long-term survivors. To identify contemporary trends in intensive care unit (ICU) use and long-term outcomes, we merged data from the Center for International Blood and Marrow Transplant Research and the Virtual Pediatric Systems databases. We identified 6995 pediatric patients with HCT aged ≤21 years who underwent first allogeneic HCT between 2008 and 2014 across 69 centers in the United States or Canada and followed patients until the year 2020. ICU admission was required for 1067 patients (8.3% by day +100, 12.8% by 1 year, and 15.3% by 5 years after HCT), and was linked to demographic background, pretransplant organ toxicity, allograft type and HLA-match, and the development of graft-versus-host disease or malignancy relapse. Survival to ICU discharge was 85.7%, but more than half of ICU survivors required ICU readmission, leading to 52.5% and 42.6% survival at 1- and 5-years post-ICU transfer, respectively. ICU survival was worse among patients with malignant disease, poor pretransplant organ function, and alloreactivity risk factors. Among 1-year HCT survivors, those who required ICU in the first year had 10% lower survival at 5 years and developed new dialysis-dependent renal failure at a greater rate (P

Published
2024

5. Effect of Autograft CD34+ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors.

Author

Knight, Tristan, Ahn, Kwang, Hebert, Kyle, Atshan, Rasha, Wall, Donna, Chiengthong, Kanhatai, Rotz, Seth, Fraint, Ellen, Rangarajan, Hemalatha, Auletta, Jeffery, Sharma, Akshay, Kitko, Carrie, Hashem, Hasan, Williams, Kirsten, Wirk, Baldeep, Myers, Kasiani, Pulsipher, Michael, Warwick, Anne, Schultz, Kirk, Qayed, Muna, Broglie, Larisa, Eapen, Mary, Yanik, Gregory, Dvorak, Christopher, and Lalefar, Nahal

Subjects
Autograft, Autologous hematopoietic stem cell transplant, CD34+, Central nervous system, Medulloblastoma, TNC, Humans, Child, Retrospective Studies, Autografts, Neoplasm Recurrence, Local, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Central Nervous System Neoplasms
Abstract

Consolidation with autologous hematopoietic stem cell transplantation (HSCT) has improved survival for patients with central nervous system tumors (CNSTs). The impact of the autologous graft CD34+ dose on patient outcomes is unknown. We wanted to analyze the relationship between CD34+ dose, total nucleated cell (TNC) dose, and clinical outcomes, including overall survival (OS), progression-free survival (PFS), relapse, non-relapse mortality (NRM), endothelial-injury complications (EIC), and time to neutrophil engraftment in children undergoing autologous HSCT for CNSTs. A retrospective analysis of the CIBMTR database was performed. Children aged 3.6×106/kg CD34+ cells experienced superior PFS (p = .04) and OS (p = .04) compared to children receiving ≤3.6 × 106/kg. Relapse rates were lower in patients receiving >3.6 × 106/kg CD34+ cells (p = .05). Higher CD34+ doses were not associated with increased NRM (p = .59). Stratification of CD34+ dose by quartile did not reveal any statistically significant differences between quartiles for 3-year PFS (p = .66), OS (p = .29), risk of relapse (p = .57), or EIC (p = .87). There were no significant differences in patient outcomes based on TNC, and those receiving a TNC >4.4 × 108/kg did not experience superior PFS (p = .26), superior OS (p = .14), reduced risk of relapse (p = .37), or reduced NRM (p = .25). Children with medulloblastoma had superior PFS (p < .001), OS (p = .01), and relapse rates (p = .001) compared to those with other CNS tumor types. Median time to neutrophil engraftment was 10 days versus 12 days in the highest and lowest infused CD34+ quartiles, respectively. For children undergoing autologous HSCT for CNSTs, increasing CD34+ cell dose was associated with significantly improved OS and PFS, and lower relapse rates, without increased NRM or EICs.

Published
2023

6. No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma

Author

Knight, Tristan E., Ahn, Kwang Woo, Hebert, Kyle M., Atshan, Rasha, Wall, Donna A., Chiengthong, Kanhatai, Lund, Troy C., Prestidge, Tim, Rangarajan, Hemalatha G., Dvorak, Christopher C., Auletta, Jeffery J., Kent, Michael, Hashem, Hasan, Talano, Julie-An, Rotz, Seth J., Fraint, Ellen, Myers, Kasiani C., Leung, Wing, Sharma, Akshay, Bhatt, Neel S., Driscoll, Timothy A., Yu, Lolie C., Schultz, Kirk R., Qayed, Muna, Broglie, Larisa, Eapen, Mary, and Yanik, Gregory A.

Published
2023
Full Text
View/download PDF

7. Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study

Author

Kahn, Justine, Brazauskas, Ruta, Bo-Subait, Stephanie, Buchbinder, David, Hamilton, Betty K, Schoemans, Hélène, Abraham, Allistair A, Agrawal, Vaibhav, Auletta, Jeffery J, Badawy, Sherif M, Beitinjaneh, Amer, Bhatt, Neel S, Broglie, Larisa, Diaz Perez, Miguel Angel, Farhadfar, Nosha, Freytes, Cesar O, Gale, Robert Peter, Ganguly, Siddhartha, Hayashi, Robert J, Hematti, Peiman, Hildebrandt, Gerhard C, Inamoto, Yoshihiro, Kamble, Rammurti T, Koo, Jane, Lazarus, Hillard M, Mayo, Samantha J, Mehta, Parinda A, Myers, Kasiani C, Nishihori, Taiga, Prestidge, Tim, Rotz, Seth J, Savani, Bipin N, Schears, Raquel M, Sharma, Akshay, Stenger, Elizabeth, Ustun, Celalettin, Williams, Kirsten M, Vrooman, Lynda M, Satwani, Prakash, and Phelan, Rachel

Published
2024
Full Text
View/download PDF

9. Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.

Author

Kennedy, Alyssa L, Myers, Kasiani C, Bowman, James, Gibson, Christopher J, Camarda, Nicholas D, Furutani, Elissa, Muscato, Gwen M, Klein, Robert H, Ballotti, Kaitlyn, Liu, Shanshan, Harris, Chad E, Galvin, Ashley, Malsch, Maggie, Dale, David, Gansner, John M, Nakano, Taizo A, Bertuch, Alison, Vlachos, Adrianna, Lipton, Jeffrey M, Castillo, Paul, Connelly, James, Churpek, Jane, Edwards, John R, Hijiya, Nobuko, Ho, Richard H, Hofmann, Inga, Huang, James N, Keel, Siobán, Lamble, Adam, Lau, Bonnie W, Norkin, Maxim, Stieglitz, Elliot, Stock, Wendy, Walkovich, Kelly, Boettcher, Steffen, Brendel, Christian, Fleming, Mark D, Davies, Stella M, Weller, Edie A, Bahl, Christopher, Carter, Scott L, Shimamura, Akiko, and Lindsley, R Coleman

Subjects
Ribosomes, Humans, Bone Marrow Diseases, Eukaryotic Initiation Factors, Mutation, Adolescent, Adult, Middle Aged, Child, Child, Preschool, Infant, Female, Male, Tumor Suppressor Protein p53, Young Adult, Shwachman-Diamond Syndrome, Clonal Hematopoiesis, Preschool
Abstract

To understand the mechanisms that mediate germline genetic leukemia predisposition, we studied the inherited ribosomopathy Shwachman-Diamond syndrome (SDS), a bone marrow failure disorder with high risk of myeloid malignancies at an early age. To define the mechanistic basis of clonal hematopoiesis in SDS, we investigate somatic mutations acquired by patients with SDS followed longitudinally. Here we report that multiple independent somatic hematopoietic clones arise early in life, most commonly harboring heterozygous mutations in EIF6 or TP53. We show that germline SBDS deficiency establishes a fitness constraint that drives selection of somatic clones via two distinct mechanisms with different clinical consequences. EIF6 inactivation mediates a compensatory pathway with limited leukemic potential by ameliorating the underlying SDS ribosome defect and enhancing clone fitness. TP53 mutations define a maladaptive pathway with enhanced leukemic potential by inactivating tumor suppressor checkpoints without correcting the ribosome defect. Subsequent development of leukemia was associated with acquisition of biallelic TP53 alterations. These results mechanistically link leukemia predisposition to germline genetic constraints on cellular fitness, and provide a rational framework for clinical surveillance strategies.

Published
2021

10. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant

Author

Dandoy, Christopher E, Rotz, Seth, Alonso, Priscila Badia, Klunk, Anna, Desmond, Catherine, Huber, John, Ingraham, Hannah, Higham, Christine, Dvorak, Christopher C, Duncan, Christine, Schoettler, Michelle, Lehmann, Leslie, Cancio, Maria, Killinger, James, Davila, Blachy, Phelan, Rachel, Mahadeo, Kris M, Khazal, Sajad, Lalefar, Nahal, Vissa, Madhav, Myers, Kasiani, Wallace, Greg, Nelson, Adam, Khandelwal, Pooja, Bhatla, Deepika, Gloude, Nicholas, Anderson, Eric, Huo, Jeffrey, Roehrs, Philip, Auletta, Jeffery J, Chima, Ranjit, Lane, Adam, Davies, Stella M, and Jodele, Sonata

Subjects
Prevention, Clinical Research, Pediatric, Regenerative Medicine, Clinical Trials and Supportive Activities, Transplantation, Cancer, Child, Hematopoietic Stem Cell Transplantation, Humans, Incidence, Male, Prospective Studies, Retrospective Studies, Thrombotic Microangiopathies
Abstract

Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of hematopoietic stem cell transplantation (HSCT). A single-center prospective screening study has shown that the incidence of TA-TMA is much higher than prior retrospective studies that did not systematically screen. These data have not been replicated in a multicenter study. Our objective was to determine the incidence and risk factors for TA-TMA and compare outcomes of pediatric HSCT patients with and without TA-TMA. Patients were prospectively screened for TA-TMA at participating centers using a simple to implement and inexpensive strategy from the start of the preparative regimen through day +100. TA-TMA was diagnosed if ≥4 of 7 laboratory/clinical markers diagnostic for TA-TMA were present concurrently or if tissue histology showed TA-TMA. A total of 614 patients (359 males; 58%) received prospective TA-TMA screening at 13 pediatric centers. TA-TMA was diagnosed in 98 patients (16%) at a median of 22 days (interquartile range, 14-44) posttransplant. Patients with TA-TMA had significantly increased bloodstream infections (38% [37/98] vs 21% [107/51], P ≤ .001), mean total hospitalization days (68; 95% confidence interval [CI], 63-74 vs 43; 95% CI, 41-45; P ≤ .001), and number of days spent in the intensive care unit (10.1; 95% CI, 6.4-14; vs 1.6; 95% CI, 1.1-2.2; P ≤ .001) in the first 100 days after HSCT compared with patients without TA-TMA. Overall survival was significantly higher in patients without TA-TMA (93%; 490/516) compared with patients with TA-TMA (78%; 76/98) (P ≤ .001). These data support the need for systematic screening for TA-TMA and demonstrate the feasibility and efficacy of an easy to implement strategy to do so.

Published
2021

12. Mouse models of neutropenia reveal progenitor-stage-specific defects.

Author

Muench, David, Olsson, Andre, Ferchen, Kyle, Pham, Giang, Serafin, Rachel, Chutipongtanate, Somchai, Dwivedi, Pankaj, Song, Baobao, Hay, Stuart, Chetal, Kashish, Trump-Durbin, Lisa, Mookerjee-Basu, Jayati, Zhang, Kejian, Yu, Jennifer, Lutzko, Carolyn, Myers, Kasiani, Nazor, Kristopher, Greis, Kenneth, Kappes, Dietmar, Way, Sing, Salomonis, Nathan, and Grimes, H

Subjects
Animals, Candida albicans, Cell Lineage, DNA-Binding Proteins, Disease Models, Animal, Female, Granulocyte Precursor Cells, Humans, Immunity, Innate, Male, Mice, Mice, Transgenic, Mutation, Neutropenia, Neutrophils, Transcription Factors
Abstract

Advances in genetics and sequencing have identified a plethora of disease-associated and disease-causing genetic alterations. To determine causality between genetics and disease, accurate models for molecular dissection are required; however, the rapid expansion of transcriptional populations identified through single-cell analyses presents a major challenge for accurate comparisons between mutant and wild-type cells. Here we generate mouse models of human severe congenital neutropenia (SCN) using patient-derived mutations in the GFI1 transcription factor. To determine the effects of SCN mutations, we generated single-cell references for granulopoietic genomic states with linked epitopes1, aligned mutant cells to their wild-type equivalents and identified differentially expressed genes and epigenetic loci. We find that GFI1-target genes are altered sequentially, as cells go through successive states of differentiation. These insights facilitated the genetic rescue of granulocytic specification but not post-commitment defects in innate immune effector function, and underscore the importance of evaluating the effects of mutations and therapy within each relevant cell state.

Published
2020

13. Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia

Author

Lund, Troy C, Ahn, Kwang Woo, Tecca, Heather R, Hilgers, Megan V, Abdel-Azim, Hisham, Abraham, Allistair, Diaz, Miguel Angel, Badawy, Sherif M, Broglie, Larisa, Brown, Valerie, Dvorak, Christopher C, Gonzalez-Vicent, Marta, Hashem, Hasan, Hayashi, Robert J, Jacobsohn, David A, Kent, Michael W, Li, Chi-Kong, Margossian, Steven P, Martin, Paul L, Mehta, Parinda, Myers, Kasiani, Olsson, Richard, Page, Kristin, Pulsipher, Michael A, Shaw, Peter J, Smith, Angela R, Triplett, Brandon M, Verneris, Michael R, and Eapen, Mary

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Transplantation, Hematology, Childhood Leukemia, Regenerative Medicine, Pediatric Cancer, Rare Diseases, Orphan Drug, Pediatric, Acute Disease, Adolescent, Adult, Child, Child, Preschool, Disease-Free Survival, Female, Hematopoietic Stem Cell Transplantation, Humans, Infant, Leukemia, Male, Recurrence, Survival Rate, Time Factors, Young Adult, relapse acute leukemia second transplant, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Children with acute leukemia who relapse after hematopoietic cell transplantation (HCT) have few therapeutic options. We studied 251 children and young adults with acute myelogenous or lymphoblastic leukemia who underwent a second HCT for relapse after their first HCT. The median age at second HCT was 11 years, and the median interval between first and second HCT was 17 months. Most of the patients (n = 187; 75%) were in remission, received a myeloablative conditioning regimen (n = 157; 63%), and underwent unrelated donor HCT (n = 230; 92%). The 2-year probability of leukemia-free survival (LFS) was 33% after transplantation in patients in remission, compared with 19% after transplantation in patients not in remission (P = .02). The corresponding 8-year probabilities were 24% and 10% (P = .003). A higher rate of relapse contributed to the difference in LFS. The 2-year probability of relapse after transplantation was 42% in patients in remission and 56% in those in relapse (P = .05). The corresponding 8-year probabilities were 49% and 64% (P = .04). These data extend the findings of others showing that patients with a low disease burden are more likely to benefit from a second transplantation. Late relapse led to a 10% decrement in LFS beyond the second year after second HCT. This differs from first HCT, in which most relapses occur within 2 years after HCT.

Published
2019

16. Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes

Author

Kapadia, Malika, Lehmann, Leslie, Auletta, Jeffery, Beatty, Lisa, Bhatt, Neel, Blacken, Robyn, Demmel, Kathy, Dodd, Therese, Desmond, Catherine, Fitch, Taylor, Flesch, Laura, Hartley, David, Huber, John, Ingraham, Hannah, Jakubowski, Rita, Klunk, Anna, Krupski, Christa, Kusnier, Katilyn, Liberio, Nicole, Maakaron, Joseph, Mueller, Mark, Myers, Kasiani C., Pai, Ahna, Parker, Loretta, Patel, Sagar, Phelan, Rachel, Polishchuk, Veronika, Sigmund, Audrey, Sper, Christine, Tarquini, Sarah, Juckett, Mark, Jaglowski, Samantha, Dandoy, Christopher, and Rotz, Seth

Published
2022
Full Text
View/download PDF

17. Autophagy in mesenchymal progenitors protects mice against bone marrow failure after severe intermittent stress

Author

Landspersky, Theresa, Saçma, Mehmet, Rivière, Jennifer, Hecker, Judith S., Hettler, Franziska, Hameister, Erik, Brandstetter, Katharina, Istvánffy, Rouzanna, Romero Marquez, Sandra, Ludwig, Romina, Götz, Marilena, Buck, Michèle, Wolf, Martin, Schiemann, Matthias, Ruland, Jürgen, Strunk, Dirk, Shimamura, Akiko, Myers, Kasiani, Yamaguchi, Terry P., Kieslinger, Matthias, Leonhardt, Heinrich, Bassermann, Florian, Götze, Katharina S., Geiger, Hartmut, Schreck, Christina, and Oostendorp, Robert A.J.

Published
2022
Full Text
View/download PDF

18. Hematologic complications with age in Shwachman-Diamond syndrome

Author

Furutani, Elissa, Liu, Shanshan, Galvin, Ashley, Steltz, Sarah, Malsch, Maggie M., Loveless, Sara K., Mount, Leann, Larson, Jordan H., Queenan, Kelan, Bertuch, Alison A., Fleming, Mark D., Gansner, John M., Geddis, Amy E., Hanna, Rabi, Keel, Sioban B., Lau, Bonnie W., Lipton, Jeffrey M., Lorsbach, Robert, Nakano, Taizo A., Vlachos, Adrianna, Wang, Winfred C., Davies, Stella M., Weller, Edie, Myers, Kasiani C., and Shimamura, Akiko

Published
2022
Full Text
View/download PDF

19. Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation

Author

Bender, Jonathan D., Toro, Helen Oquendo-del, Benoit, Janie, Howell, Jonathan C., Badia, Priscila, Davies, Stella M., Grimley, Michael S., Jodele, Sonata, Phillips, Christine, Burns, Karen, Marsh, Rebecca, Nelson, Adam, Wallace, Gregory, Dandoy, Christopher E., Pate, Abigail, Strine, Andrew C., Frias, Olivia, Breech, Lesley, Rose, Susan R., Hoefgen, Holly, Khandelwal, Pooja, and Myers, Kasiani C.

Published
2022
Full Text
View/download PDF

20. Fertility Potential and Gonadal Function in Survivors of Reduced-Intensity Hematopoietic Stem Cell Transplantation

Author

Rotz, Seth J., Hamilton, Betty K., Wei, Wei, Ahmed, Ibrahim, Winston, Sameeya Ahmed, Ballard, Sherri, Bernard, Robyn J., Carpenter, Paul, Farhadfar, Nosha, Ferraro, Christina, Friend, Brian D., Gloude, Nicholas J., Hayashi, Robert J., Hoyle, Kerry, Jenssen, Kari, Koo, Jane, Lee, Catherine J., Mariano, Livia, Nawabit, Rawan, Ngwube, Alexander, Lalefar, Nahal, Phelan, Rachel, Perkins, Laynie, Rao, Anandini, Rayes, Ahmad, Sandheinrich, Taryn, Stafford, Lauren, Tomlinson, Kathryn, Whiteside, Stacy, Wiedl, Christina, and Myers, Kasiani

Published
2024
Full Text
View/download PDF

21. Outcomes of pediatric patients with therapy-related myeloid neoplasms

Author

Sharma, Akshay, Huang, Sujuan, Li, Ying, Brooke, Russell J., Ahmed, Ibrahim, Allewelt, Heather B., Amrolia, Persis, Bertaina, Alice, Bhatt, Neel S., Bierings, Marc B., Bies, Joshua, Brisset, Claire, Brondon, Jennifer E., Dahlberg, Ann, Dalle, Jean-Hugues, Eissa, Hesham, Fahd, Mony, Gassas, Adam, Gloude, Nicholas J., Goebel, W. Scott, Goeckerman, Erika S., Harris, Katherine, Ho, Richard, Hudspeth, Michelle P., Huo, Jeffrey S., Jacobsohn, David, Kasow, Kimberly A., Katsanis, Emmanuel, Kaviany, Saara, Keating, Amy K., Kernan, Nancy A., Ktena, Yiouli P., Lauhan, Colette R., López-Hernandez, Gerardo, Martin, Paul L., Myers, Kasiani C., Naik, Swati, Olaya-Vargas, Alberto, Onishi, Toshihiro, Radhi, Mohamed, Ramachandran, Shanti, Ramos, Kristie, Rangarajan, Hemalatha G., Roehrs, Philip A., Sampson, Megan E., Shaw, Peter J., Skiles, Jodi L., Somers, Katherine, Symons, Heather J., de Tersant, Marie, Uber, Allison N., Versluys, Birgitta, Cheng, Cheng, and Triplett, Brandon M.

Published
2021
Full Text
View/download PDF

24. Neutropenia and intellectual disability are hallmarks of biallelic and de novo CLPB deficiency

Author

Wortmann, Saskia B., Ziętkiewicz, Szymon, Guerrero-Castillo, Sergio, Feichtinger, René G., Wagner, Matias, Russell, Jacqui, Ellaway, Carolyn, Mróz, Dagmara, Wyszkowski, Hubert, Weis, Denisa, Hannibal, Iris, von Stülpnagel, Celina, Cabrera-Orefice, Alfredo, Lichter-Konecki, Uta, Gaesser, Jenna, Windreich, Randy, Myers, Kasiani C., Lorsbach, Robert, Dale, Russell C., Gersting, Søren, Prada, Carlos E., Christodoulou, John, Wolf, Nicole I., Venselaar, Hanka, Mayr, Johannes A., and Wevers, Ron A.

Published
2021
Full Text
View/download PDF

25. Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders

Author

Himes, Ryan W., Chiou, Eric H., Queliza, Karen, Shouval, Dror S., Somech, Raz, Agarwal, Suneet, Jajoo, Kunal, Ziegler, David S., Kratz, Christian P., Huang, James, Lucas, Tiffany L., Myers, Kasiani C., Nelson, Adam S., DiNardo, Courtney D., Alter, Blanche P., Giri, Neelam, Khincha, Payal P., McReynolds, Lisa J., Dufour, Carlo, Pierri, Filomena, Goldman, Frederick D., Sherif, Youmna, Savage, Sharon A., Miloh, Tamir, and Bertuch, Alison A.

Published
2021
Full Text
View/download PDF

26. Early career mentoring through the American Society of Pediatric Hematology/Oncology: Lessons learned from a pilot program

Author

Badawy, Sherif M, Black, Vandy, Meier, Emily R, Myers, Kasiani C, Pinkney, Kerice, Hastings, Caroline, Hilden, Joanne M, Zweidler‐McKay, Patrick, Stork, Linda C, Johnson, Theodore S, and Vaiselbuh, Sarah R

Subjects
Paediatrics, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Hematology, Cancer, Pediatric Research Initiative, Career Choice, Female, Humans, Male, Medical Oncology, Mentoring, Mentors, Pediatrics, Personal Satisfaction, Pilot Projects, Program Evaluation, career development, early career, fellow, junior faculty, mentoring, mentorship, pediatric hematology oncology, pediatric subspecialty, trainee, Clinical Sciences, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Effective networking and mentorship are critical determinants of career satisfaction and success in academic medicine. The American Society of Pediatric Hematology/Oncology (ASPHO) mentoring program was developed to support Early Career (EC) members. Herein, the authors report on the initial 2-year outcomes of this novel program. Mentees selected mentors with expertise in different subspecialties within the field from mentor profiles at the ASPHO Web site. Of 23 enrolled pairs, 19 mentors and 16 mentees completed electronic program feedback evaluations. The authors analyzed data collected between February 2013 and December 2014. The authors used descriptive statistics for categorical data and thematic analysis for qualitative data. The overall response rate was 76% (35/46). At the initiation of the relationship, career development and research planning were the most commonly identified goals for both mentors and mentees. Participants communicated by phone, e-mail, or met in-person at ASPHO annual meetings. Most mentor-mentee pairs were satisfied with the mentoring relationship, considered it a rewarding experience that justified their time and effort, achieved their goals in a timely manner with objective work products, and planned to continue the relationship. However, time constraints and infrequent communications remained a challenge. Participation in the ASPHO mentoring program suggests a clear benefit to a broad spectrum of ASPHO EC members with diverse personal and professional development needs. Efforts to expand the mentoring program are ongoing and focused on increasing enrollment of mentors to cover a wider diversity of career tracks/subspecialties and evaluating career and academic outcomes more objectively.

Published
2017

32. Increased Body Mass Index Augments Endothelial Injury and Clinical Outcomes after Hematopoietic Stem Cell Transplantation

Author

Koo, Jane, Ziady, Assem G., Reynaud, Damien, Abdullah, Sheyar, Luebbering, Nathan, Kahn, Seth, Langenberg, Lucille, Strecker, Lauren, Lake, Kelly, Dandoy, Christopher E., Lane, Adam, Myers, Kasiani C., Sabulski, Anthony, Good, Samantha, Nalapareddy, Kodandaramireddy, Solomon, Michael, Siefert, Matthew E., Skala, Emily, Jodele, Sonata, and Davies, Stella M.

Published
2023
Full Text
View/download PDF

34. Treatment of relapsed/refractory severe aplastic anemia in children: Evidence‐based recommendations.

Author

Shimano, Kristin A., Sasa, Ghadir, Broglie, Larisa, Gloude, Nicholas J., Myers, Kasiani, Nakano, Taizo A., Sharathkumar, Anjali, Rothman, Jennifer A., Pereda, Maria A., Overholt, Kathleen, Narla, Anupama, McGuinn, Catherine, Lau, Bonnie W., Geddis, Amy E., Dror, Yigal, de Jong, Jill L. O., Castillo, Paul, Allen, Steven W., and Boklan, Jessica

Published
2024
Full Text
View/download PDF

37. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases

Author

Kahn, Justine M., Brazauskas, Ruta, Tecca, Heather R., Bo-Subait, Stephanie, Buchbinder, David, Battiwala, Minoo, Flowers, Mary E.D., Savani, Bipin N., Phelan, Rachel, Broglie, Larisa, Abraham, Allistair A., Keating, Amy K., Daly, Andrew, Wirk, Baldeep, George, Biju, Alter, Blanche P., Ustun, Celalettin, Freytes, Cesar O., Beitinjaneh, Amer M., Duncan, Christine, Copelan, Edward, Hildebrandt, Gerhard C., Murthy, Hemant S., Lazarus, Hillard M., Auletta, Jeffery J., Myers, Kasiani C., Williams, Kirsten M., Page, Kristin M., Vrooman, Lynda M., Norkin, Maxim, Byrne, Michael, Diaz, Miguel Angel, Kamani, Naynesh, Bhatt, Neel S., Rezvani, Andrew, Farhadfar, Nosha, Mehta, Parinda A., Hematti, Peiman, Shaw, Peter J., Kamble, Rammurti T., Schears, Raquel, Olsson, Richard F., Hayashi, Robert J., Gale, Robert Peter, Mayo, Samantha J., Chhabra, Saurabh, Rotz, Seth J., Badawy, Sherif M., Ganguly, Siddhartha, Pavletic, Steven, Nishihori, Taiga, Prestidge, Tim, Agrawal, Vaibhav, Hogan, William J., Inamoto, Yoshihiro, Shaw, Bronwen E., and Satwani, Prakash

Published
2020
Full Text
View/download PDF

38. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study

Author

Myers, Kasiani C, Furutani, Elissa, Weller, Edie, Siegele, Bradford, Galvin, Ashley, Arsenault, Valerie, Alter, Blanche P, Boulad, Farid, Bueso-Ramos, Carlos, Burroughs, Lauri, Castillo, Paul, Connelly, James, Davies, Stella M, DiNardo, Courtney D, Hanif, Iftikhar, Ho, Richard H, Karras, Nicole, Manalang, Michelle, McReynolds, Lisa J, Nakano, Taizo A, Nalepa, Grzegorz, Norkin, Maxim, Oberley, Matthew J, Orgel, Etan, Pastore, Yves D, Rosenthal, Joseph, Walkovich, Kelly, Larson, Jordan, Malsch, Maggie, Elghetany, M Tarek, Fleming, Mark D, and Shimamura, Akiko

Published
2020
Full Text
View/download PDF

39. Effect of Autograft CD34+ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors

Author

Knight, Tristan E., Ahn, Kwang Woo, Hebert, Kyle M., Atshan, Rasha, Wall, Donna A., Chiengthong, Kanhatai, Rotz, Seth J., Fraint, Ellen, Rangarajan, Hemalatha G., Auletta, Jeffery J., Sharma, Akshay, Kitko, Carrie L., Hashem, Hasan, Williams, Kirsten M., Wirk, Baldeep, Dvorak, Christopher C., Myers, Kasiani C., Pulsipher, Michael A., Warwick, Anne B., Lalefar, Nahal Rose, Schultz, Kirk R., Qayed, Muna, Broglie, Larisa, Eapen, Mary, and Yanik, Gregory A.

Published
2023
Full Text
View/download PDF

42. CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study

Author

Khandelwal, Pooja, Fukuda, Tsuyoshi, Teusink-Cross, Ashley, Kashuba, Angela D. M., Lane, Adam, Mehta, Parinda A., Marsh, Rebecca A., Jordan, Michael B., Grimley, Michael S., Myers, Kasiani C., Nelson, Adam S., El-Bietar, Javier, Chandra, Sharat, Bleesing, Jacob J., Krupski, Mary C., and Davies, Stella M.

Published
2020
Full Text
View/download PDF

44. Mouse models of neutropenia reveal progenitor-stage-specific defects

Author

Muench, David E., Olsson, Andre, Ferchen, Kyle, Pham, Giang, Serafin, Rachel A., Chutipongtanate, Somchai, Dwivedi, Pankaj, Song, Baobao, Hay, Stuart, Chetal, Kashish, Trump-Durbin, Lisa R., Mookerjee-Basu, Jayati, Zhang, Kejian, Yu, Jennifer C., Lutzko, Carolyn, Myers, Kasiani C., Nazor, Kristopher L., Greis, Kenneth D., Kappes, Dietmar J., Way, Sing Sing, Salomonis, Nathan, and Grimes, H. Leighton

Published
2020
Full Text
View/download PDF

45. On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology

Author

Chou, David B., Frismantas, Viktoras, Milton, Yuka, David, Rhiannon, Pop-Damkov, Petar, Ferguson, Douglas, MacDonald, Alexander, Vargel Bölükbaşı, Özge, Joyce, Cailin E., Moreira Teixeira, Liliana S., Rech, Arianna, Jiang, Amanda, Calamari, Elizabeth, Jalili-Firoozinezhad, Sasan, Furlong, Brooke A., O’Sullivan, Lucy R., Ng, Carlos F., Choe, Youngjae, Marquez, Susan, Myers, Kasiani C., Weinberg, Olga K., Hasserjian, Robert P., Novak, Richard, Levy, Oren, Prantil-Baun, Rachelle, Novina, Carl D., Shimamura, Akiko, Ewart, Lorna, and Ingber, Donald E.

Published
2020
Full Text
View/download PDF

50. Somatic mutations and clonal hematopoiesis in congenital neutropenia

Author

Xia, Jun, Miller, Christopher A., Baty, Jack, Ramesh, Amrita, Jotte, Matthew R.M., Fulton, Robert S., Vogel, Tiphanie P., Cooper, Megan A., Walkovich, Kelly J., Makaryan, Vahagn, Bolyard, Audrey A., Dinauer, Mary C., Wilson, David B., Vlachos, Adrianna, Myers, Kasiani C., Rothbaum, Robert J., Bertuch, Alison A., Dale, David C., Shimamura, Akiko, Boxer, Laurence A., and Link, Daniel C.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results